 HOUSTON, Sept. 30, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Childrens Hospital disclosed today that an abstract has been accepted by the American Association for Cancer Research AACR for poster presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The abstract highlights research into the ability of Salarius lead drug candidate, seclidemstat SP-2577, to target FET-rearranged sarcomas through the inhibition of the non-enzymatic function i.e., scaffolding function of the LSD1 enzyme. The conference will take place virtually October 710, 2021. 